Prospective Grant of Exclusive Patent License: Treatment of Hermansky-Pudlak Syndrome and Idiopathic Pulmonary Fibrosis, 71079-71080 [2020-24616]
Download as PDF
<![CDATA[
71079
Federal Register / Vol. 85, No. 216 / Friday, November 6, 2020 / Notices
Agenda: To review and evaluate grant
applications.
Place: Video Assisted Meeting.
Contact Person: Leonid V. Tsap, Ph.D.,
Scientific Review Officer, Extramural
Programs, National Library of Medicine, NIH,
6705 Rockledge Drive, Suite 500, Bethesda,
MD 20892–7968, 301–827–7077, tsapl@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.879, Medical Library
Assistance, National Institutes of Health,
HHS)
Dated: November 2, 2020.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–24669 Filed 11–5–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Clinical trials
for COVID 19 management in older
individuals.
Date: December 11, 2020.
Time: 10:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Maurizio Grimaldi, MD,
Ph.D., Scientific Review Officer, Scientific
Review Branch, National Institute on Aging,
National Institutes of Health, 7201 Wisconsin
Avenue, Gateway Building, Suite 2W200,
Bethesda, MD 20892, (301) 496–9374,
grimaldim2@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: November 2, 2020.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–24615 Filed 11–5–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
SUMMARY: The National Heart, Lung and
Blood Institute (NHLBI) and the
National Human Genome Research
Institute (NHGRI), both of the National
Institutes of Health, Department of
Health and Human Services, are
contemplating the grant of an exclusive
patent license to Inversago Pharma Inc.,
located in Montreal, Quebec, Canada, to
practice the inventions embodied in the
patent applications listed in the
SUPPLEMENTARY INFORMATION section of
this notice.
Only written comments and/or
applications for a license which are
received by the National Human
Genome Research Institute’s Technology
Transfer Office on or before November
23, 2020 will be considered.
DATES:
Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
exclusive patent license should be
directed to: Anna Solowiej, Ph.D., J.D.,
Senior Licensing and Patenting
Manager, NHGRI Technology Transfer
Office; Telephone (301) 435–7791;
Email: anna.solowiej@nih.gov.
ADDRESSES:
The
following and all continuing U.S. and
foreign patents/patent applications
thereof are the intellectual properties to
be licensed under the prospective
agreement to Inversago Pharma Inc.:
Prospective Grant of Exclusive Patent
License: Treatment of HermanskyPudlak Syndrome and Idiopathic
Pulmonary Fibrosis
National Institutes of Health,
HHS.
NIH ref No.
Patent No. or
application No.
Issue date
Filing date
E–282–2012–0–US–01 ..........
E–282–2012–0–PCT–02 ........
E–282–2012–0–US–03 ..........
E–282–2012–0–CA–04 ..........
E–282–2012–0–EP–05 ..........
E–282–2012–0–CH–12 ..........
E–282–2012–0–DE–13 ..........
E–282–2012–0–FR–14 ..........
E–282–2012–0–GB–15 ..........
E–282–2012–0–IE–16 ...........
E–282–2012–0–IN–06 ...........
E–282–2012–0–JP–07 ...........
E–282–2012–0–CN–08 ..........
E–282–2012–0–US–09 ..........
E–282–2012–0–US–10 ..........
E–282–2012–0–US–11 ..........
E–282–2012–1–US–01 ..........
E–282–2012–1–PCT–02 ........
E–282–2012–1–EP–05 ..........
E–282–2012–1–US–08 ..........
E–282–2012–1–US–09 ..........
E–282–2012–2–US–01 ..........
E–282–2012–2–PCT–02 ........
E–282–2012–2–CN–03 ..........
E–282–2012–2–EP–04 ..........
E–140–2014–0–US–01 ..........
E–140–2014–0–PCT–02 ........
E–140–2014–0–AU–03 ..........
E–140–2014–0–CA–04 ..........
E–140–2014–0–CN–05 ..........
61/725,949 ....................
PCT/US2013/069686 ...
9,765,031 ......................
2889697 ........................
13802153.0 ...................
13802153.0 ...................
13802153.0 ...................
13802153.0 ...................
13802153.0 ...................
13802153.0 ...................
3733/DELNP/2015 ........
6272626 ........................
ZL201380069389.9 ......
10,683,270 ....................
15/674,333 ....................
16/870,093 ....................
62/171,179 ....................
PCT/US2016/035291 ...
16728547.7 ...................
15/579,123 ....................
16/438,850 ....................
15/061,829 ....................
PCT/US2017/020250 ...
2017800118698 ............
17711443.6 ...................
61/991,333 ....................
PCT/US2015/029946 ...
2015255765 ..................
2948349 ........................
201580028788.X ..........
...............................................
...............................................
September 19, 2017 ............
...............................................
TBD ......................................
TBD ......................................
TBD ......................................
TBD ......................................
TBD ......................................
TBD ......................................
...............................................
January 12, 2018 .................
August 20, 2019 ...................
June 16, 2020 ......................
TBD (application allowed) ....
...............................................
...............................................
...............................................
...............................................
...............................................
...............................................
...............................................
...............................................
...............................................
...............................................
...............................................
...............................................
...............................................
...............................................
February 7, 2020 ..................
November 13, 2012 ......
November 12, 2013 ......
November 12, 2013 ......
April 27, 2015 ...............
June 01, 2015 ..............
November 12, 2013 ......
November 12, 2013 ......
November 12, 2013 ......
November 12, 2013 ......
November 12, 2013 ......
May 1, 2015 .................
May 11, 2015 ...............
July 3, 2015 ..................
August 10, 2017 ...........
August 10, 2017 ...........
May 8, 2020 .................
June 4, 2015 ................
June 1, 2016 ................
June 1, 2016 ................
December 1, 2017 ........
June 12, 2019 ..............
March 4, 2016 ..............
March 1, 2017 ..............
March 1, 2017 ..............
March 1, 2017 ..............
May 9, 2014 .................
May 8, 2015 .................
November 7, 2016 ........
May 8, 2015 .................
May 8, 2015 .................
VerDate Sep<11>2014
19:00 Nov 05, 2020
Jkt 253001
Notice.
SUPPLEMENTARY INFORMATION:
National Institutes of Health
AGENCY:
ACTION:
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
Title
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
E:\FR\FM\06NON1.SGM
06NON1
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
71080
Federal Register / Vol. 85, No. 216 / Friday, November 6, 2020 / Notices
NIH ref No.
Patent No. or
application No.
Issue date
Filing date
E–140–2014–0–EP–06 ..........
E–140–2014–0–IN–07 ...........
E–140–2014–0–JP–08 ...........
E–140–2014–0–US–09 ..........
E–140–2014–0–HK–10 ..........
E–140–2014–0–AU–11 ..........
15728668.3 ...................
201637038171 ..............
2017–511558 ................
10,329,259 ....................
17105705.6 ...................
2019227889 ..................
...............................................
...............................................
TBD (application allowed) ....
June 25, 2019 ......................
...............................................
...............................................
May 8, 2015 .................
November 8, 2016 ........
May 8, 2015 .................
November 8, 2016 ........
June 9, 2017 ................
May 8, 2015 .................
The patent rights in these inventions
have been assigned to the Government
of the United States of America.
The prospective exclusive patent
license territory may be worldwide and
a field of use limited to human
therapeutics for Hermansky-Pudlak
syndrome and idiopathic pulmonary
fibrosis.The invention covered by the
patents and patent applications
pertaining to HHS Ref. No. E–282–2012
relates to cannabinoid receptor 1 (CB1R)
inverse agonists. CB1R activation plays
a key role in appetitive behavior,
metabolism, and tissue fibrosis. Of
importance as a therapeutic target here
is that the receptor is expressed in both
peripheral tissue as well as the central
nervous system. The invention is a class
of pyrazole compounds that act as CB1
receptor inverse agonists and have been
shown effective at reducing obesity and
its associated metabolic consequences
while having no experimentally
discernable neuropsychotropic side
effects that are considered adverse,
unlike the earlier antagonists
rimonabant. These CB1R receptor
compounds were developed with the
goals of limiting their brain penetrance
without losing their metabolic efficacy
due to CB1 inverse agonism, and having
a primary metabolite directly targeting
enzymes involved in inflammatory and
fibrotic processes associated with
metabolic and other disorders. The
patents are both compositions of matter
and methods of use.
The inventions covered by HHS Ref.
E–140–2014–0 also pertain to pyrazole
CB1R receptor inverse agonists. In
addition, some of these compounds also
have a direct inhibitory effect on
inducible nitric oxide synthase (iNOS),
whereas another group of the
compounds directly activates AMP
kinase. There is evidence that the
metabolic effects of endocannabinoids
are mediated by CB1 receptors in
peripheral tissues. These dual-target
compounds may be useful for treating
metabolic disease and related
conditions such as obesity and diabetes
and their complications, including
various forms of tissue fibrosis, without
the dangerous side effects. This notice is
made in accordance with 35 U.S.C. 209
and 37 CFR part 404. The prospective
exclusive patent license will be royalty
VerDate Sep<11>2014
19:00 Nov 05, 2020
Jkt 253001
bearing and may be granted unless
within fifteen (15) days from the date of
this published notice, NHGRI receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR part 404.
Complete applications for a license in
the prospective field of use that are
timely filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive patent
license.
Comments and objections submitted
to this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: November 2, 2020
Claire T. Driscoll,
Director, Technology Transfer Office,
National Human Genome Research Institute.
[FR Doc. 2020–24616 Filed 11–5–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
R13 Conferences and Scientific Meetings.
Date: December 11–14, 2020.
Time: 11:00 a.m. to 7:30 p.m.
Agenda: To review and evaluate grant
applications.
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
Title
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Place: National Institutes of Health,
Rockledge I, 6705 Rockledge Drive, Bethesda,
MD 20814 (Virtual Meeting).
Contact Person: Keith A Mintzer, Ph.D.,
Scientific Review Officer, Office of Review
Branch/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health,
6705 Rockledge Drive, Room 207–G,
Bethesda, MD 20892–7924, (301) 827–7949,
mintzerk@nhlbi.nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
NHLBI Institutional Training Grants.
Date: December 15, 2020.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge I, 6705 Rockledge Drive, Bethesda,
MD 20892 (Virtual Meeting).
Contact Person: Giuseppe Pintucci, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health,
6705 Rockledge Drive, Room 205–H,
Bethesda, MD 20892, (301) 827–7969,
Pintuccig@nhlbi.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: November 2, 2020.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–24670 Filed 11–5–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
E:\FR\FM\06NON1.SGM
06NON1
]]>Agencies
[Federal Register Volume 85, Number 216 (Friday, November 6, 2020)]
[Notices]
[Pages 71079-71080]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-24616]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent License: Treatment of
Hermansky-Pudlak Syndrome and Idiopathic Pulmonary Fibrosis
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Heart, Lung and Blood Institute (NHLBI) and the
National Human Genome Research Institute (NHGRI), both of the National
Institutes of Health, Department of Health and Human Services, are
contemplating the grant of an exclusive patent license to Inversago
Pharma Inc., located in Montreal, Quebec, Canada, to practice the
inventions embodied in the patent applications listed in the
SUPPLEMENTARY INFORMATION section of this notice.
DATES: Only written comments and/or applications for a license which
are received by the National Human Genome Research Institute's
Technology Transfer Office on or before November 23, 2020 will be
considered.
ADDRESSES: Requests for copies of the patent applications, inquiries,
and comments relating to the contemplated exclusive patent license
should be directed to: Anna Solowiej, Ph.D., J.D., Senior Licensing and
Patenting Manager, NHGRI Technology Transfer Office; Telephone (301)
435-7791; Email: [email protected].
SUPPLEMENTARY INFORMATION: The following and all continuing U.S. and
foreign patents/patent applications thereof are the intellectual
properties to be licensed under the prospective agreement to Inversago
Pharma Inc.:
----------------------------------------------------------------------------------------------------------------
Patent No. or
NIH ref No. application No. Issue date Filing date Title
----------------------------------------------------------------------------------------------------------------
E-282-2012-0-US-01............. 61/725,949....... ................. November 13, 2012 Cannabinoid Receptor
Mediating Compounds.
E-282-2012-0-PCT-02............ PCT/US2013/069686 ................. November 12, 2013 Cannabinoid Receptor
Mediating Compounds.
E-282-2012-0-US-03............. 9,765,031........ September 19, November 12, 2013 Cannabinoid Receptor
2017. Mediating Compounds.
E-282-2012-0-CA-04............. 2889697.......... ................. April 27, 2015... Cannabinoid Receptor
Mediating Compounds.
E-282-2012-0-EP-05............. 13802153.0....... TBD.............. June 01, 2015.... Cannabinoid Receptor
Mediating Compounds.
E-282-2012-0-CH-12............. 13802153.0....... TBD.............. November 12, 2013 Cannabinoid Receptor
Mediating Compounds.
E-282-2012-0-DE-13............. 13802153.0....... TBD.............. November 12, 2013 Cannabinoid Receptor
Mediating Compounds.
E-282-2012-0-FR-14............. 13802153.0....... TBD.............. November 12, 2013 Cannabinoid Receptor
Mediating Compounds.
E-282-2012-0-GB-15............. 13802153.0....... TBD.............. November 12, 2013 Cannabinoid Receptor
Mediating Compounds.
E-282-2012-0-IE-16............. 13802153.0....... TBD.............. November 12, 2013 Cannabinoid Receptor
Mediating Compounds.
E-282-2012-0-IN-06............. 3733/DELNP/2015.. ................. May 1, 2015...... Cannabinoid Receptor
Mediating Compounds.
E-282-2012-0-JP-07............. 6272626.......... January 12, 2018. May 11, 2015..... Cannabinoid Receptor
Mediating Compounds.
E-282-2012-0-CN-08............. ZL201380069389.9. August 20, 2019.. July 3, 2015..... Cannabinoid Receptor
Mediating Compounds.
E-282-2012-0-US-09............. 10,683,270....... June 16, 2020.... August 10, 2017.. Cannabinoid Receptor
Mediating Compounds.
E-282-2012-0-US-10............. 15/674,333....... TBD (application August 10, 2017.. Cannabinoid Receptor
allowed). Mediating Compounds.
E-282-2012-0-US-11............. 16/870,093....... ................. May 8, 2020...... Cannabinoid Receptor
Mediating Compounds.
E-282-2012-1-US-01............. 62/171,179....... ................. June 4, 2015..... Cannabinoid Receptor
Mediating Compounds.
E-282-2012-1-PCT-02............ PCT/US2016/035291 ................. June 1, 2016..... Cannabinoid Receptor
Mediating Compounds.
E-282-2012-1-EP-05............. 16728547.7....... ................. June 1, 2016..... Cannabinoid Receptor
Mediating Compounds.
E-282-2012-1-US-08............. 15/579,123....... ................. December 1, 2017. Cannabinoid Receptor
Mediating Compounds.
E-282-2012-1-US-09............. 16/438,850....... ................. June 12, 2019.... Cannabinoid Receptor
Mediating Compounds.
E-282-2012-2-US-01............. 15/061,829....... ................. March 4, 2016.... Cannabinoid Receptor
Mediating Compounds.
E-282-2012-2-PCT-02............ PCT/US2017/020250 ................. March 1, 2017.... Cannabinoid Receptor
Mediating Compounds.
E-282-2012-2-CN-03............. 2017800118698.... ................. March 1, 2017.... Cannabinoid Receptor
Mediating Compounds.
E-282-2012-2-EP-04............. 17711443.6....... ................. March 1, 2017.... Cannabinoid Receptor
Mediating Compounds.
E-140-2014-0-US-01............. 61/991,333....... ................. May 9, 2014...... Cannabinoid Receptor
Mediating Compounds.
E-140-2014-0-PCT-02............ PCT/US2015/029946 ................. May 8, 2015...... Cannabinoid Receptor
Mediating Compounds.
E-140-2014-0-AU-03............. 2015255765....... ................. November 7, 2016. Cannabinoid Receptor
Mediating Compounds.
E-140-2014-0-CA-04............. 2948349.......... ................. May 8, 2015...... Cannabinoid Receptor
Mediating Compounds.
E-140-2014-0-CN-05............. 201580028788.X... February 7, 2020. May 8, 2015...... Cannabinoid Receptor
Mediating Compounds.
[[Page 71080]]
E-140-2014-0-EP-06............. 15728668.3....... ................. May 8, 2015...... Cannabinoid Receptor
Mediating Compounds.
E-140-2014-0-IN-07............. 201637038171..... ................. November 8, 2016. Cannabinoid Receptor
Mediating Compounds.
E-140-2014-0-JP-08............. 2017-511558...... TBD (application May 8, 2015...... Cannabinoid Receptor
allowed). Mediating Compounds.
E-140-2014-0-US-09............. 10,329,259....... June 25, 2019.... November 8, 2016. Cannabinoid Receptor
Mediating Compounds.
E-140-2014-0-HK-10............. 17105705.6....... ................. June 9, 2017..... Cannabinoid Receptor
Mediating Compounds.
E-140-2014-0-AU-11............. 2019227889....... ................. May 8, 2015...... Cannabinoid Receptor
Mediating Compounds.
----------------------------------------------------------------------------------------------------------------
The patent rights in these inventions have been assigned to the
Government of the United States of America.
The prospective exclusive patent license territory may be worldwide
and a field of use limited to human therapeutics for Hermansky-Pudlak
syndrome and idiopathic pulmonary fibrosis.The invention covered by the
patents and patent applications pertaining to HHS Ref. No. E-282-2012
relates to cannabinoid receptor 1 (CB1R) inverse agonists.
CB1R activation plays a key role in appetitive behavior,
metabolism, and tissue fibrosis. Of importance as a therapeutic target
here is that the receptor is expressed in both peripheral tissue as
well as the central nervous system. The invention is a class of
pyrazole compounds that act as CB1 receptor inverse agonists and have
been shown effective at reducing obesity and its associated metabolic
consequences while having no experimentally discernable
neuropsychotropic side effects that are considered adverse, unlike the
earlier antagonists rimonabant. These CB1R receptor
compounds were developed with the goals of limiting their brain
penetrance without losing their metabolic efficacy due to CB1 inverse
agonism, and having a primary metabolite directly targeting enzymes
involved in inflammatory and fibrotic processes associated with
metabolic and other disorders. The patents are both compositions of
matter and methods of use.
The inventions covered by HHS Ref. E-140-2014-0 also pertain to
pyrazole CB1R receptor inverse agonists. In addition, some
of these compounds also have a direct inhibitory effect on inducible
nitric oxide synthase (iNOS), whereas another group of the compounds
directly activates AMP kinase. There is evidence that the metabolic
effects of endocannabinoids are mediated by CB1 receptors in peripheral
tissues. These dual-target compounds may be useful for treating
metabolic disease and related conditions such as obesity and diabetes
and their complications, including various forms of tissue fibrosis,
without the dangerous side effects. This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive
patent license will be royalty bearing and may be granted unless within
fifteen (15) days from the date of this published notice, NHGRI
receives written evidence and argument that establishes that the grant
of the license would not be consistent with the requirements of 35
U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in the prospective field of use
that are timely filed in response to this notice will be treated as
objections to the grant of the contemplated exclusive patent license.
Comments and objections submitted to this notice will not be made
available for public inspection and, to the extent permitted by law,
will not be released under the Freedom of Information Act, 5 U.S.C.
552.
Dated: November 2, 2020
Claire T. Driscoll,
Director, Technology Transfer Office, National Human Genome Research
Institute.
[FR Doc. 2020-24616 Filed 11-5-20; 8:45 am]
BILLING CODE 4140-01-P
